FCS Press Releases

Florida Cancer Specialists and Research Institute participation in clinical trials leads to FDA approval of polatuzumab vedotin.

A panel of multidisciplinary experts have reviewed previous American Society of Clinical Oncology (ASCO) guidelines for treating anxiety and depression in adult cancer survivors. The Practice Guidelines Implementation Network (PGIN) committee, which includes Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Barry Berman, MD, MS, released updates to the pre-existing guidelines last revised in 2014 in the abstract: “Management of Anxiety and Depression in Adult Survivors of Cancer: ASCO Guideline Update.”

Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Richard McDonough, MD, is the recipient of the Florida Society of Clinical Oncology (FLASCO) 2023 Dorothy Green Phillips Legacy Award. The recognition was announced at FLASCO’s Annual Gala held on April 14 in Orlando.

New study on myelosuppression from chemo for small cell lung cancer.

FCS members envision the next 20 years of community oncology care at 2023 COA conference.

Pharmacy experts and leaders from Florida Cancer Specialists & Research Institute (FCS) will join with colleagues this week to share the latest advances in oncology pharmacy operations and dispensing practices at the  NCODA 2023 Spring Forum in Indianapolis.

A television commercial produced by Florida Cancer Specialists & Research Institute, LLC (FCS) has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.

Florida Cancer Specialists & Research Institute, LLC (FCS) has appointed Sachin Kamath, MD as Chairman of the FCS Executive Board Compliance Committee, effective February 16, 2023.

Florida Cancer Specialists & Research Institute, LLC (FCS), a consistent top performer among the 126 U.S.-based oncology practices that participated in the Center for Medicare & Medicaid Innovation (CMMI) Oncology Care Model (OCM), shares its results in the payment and delivery model’s final wave which ended in June 2022 in a newly released case study.

Research conducted through the Florida Cancer Specialists & Research Institute were featured recently at two global gatherings sponsored by the American Society of Clinical Oncology (ASCO®).

FDA approved the first Non-Covalent (Reversible) BTK inhibitor for the treatment of Relapsed or Refractory Mantle Cell Lymphoma in adult patients.

Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

Florida Cancer Specialists & Research Institute, LLC (FCS) welcomes Board-certified hematologist and medical oncologist Pavankumar Tandra, MD to the statewide practice. He is providing care to patients at the Sarasota Downtown clinic located at 1970 Golf Street, Sarasota, FL 34236.

Florida Cancer Specialists & Research Institute, LLC (FCS) announced today that Lucio Gordan, MD has assumed the role of President & Managing Physician, effective January 16, 2023.

Florida Cancer Specialists & Research Institute, LLC (FCS) has announced the promotion of Trevor Heritage, PhD to Senior Vice President & Data Officer.

Florida Cancer Specialists & Research Institute, LLC (FCS) is pleased to welcome newly appointed members, Pareshkumar (Paresh) Patel, MD and Andres Soriano, MD, to its Executive Board, effective January 1, 2023.